The infrastructure of delivering immuno-oncology therapies is equal in importance to the science. the industry must develop clear plans for delivery, pricing and reimbursement for commercialisation to be a reality
A lot of the discussion around the development of Immuno-oncology therapies centres on ‘the science’ but what of the infrastructure for delivering these treatments?
Without clear plans for delivery, pricing and reimbursement, the science may never realise its potential.
We spoke with Dr Lee Schwartzberg from the West Cancer Centre earlier this year to discuss just this. In this video, Lee gives his unique perspective on delivering innovative therapies in the ‘real world’ and the critical role of clinicians and other healthcare specialists in successful delivery. He also discusses the evolution from volume to value-based pricing, a critical step in the successful delivery of IO therapies.
Four big questions are discussed:
- What do we need to think about aside from the science when delivering IO therapies to patients?
- What can developers do to better educate and support clinical specialists and those that deliver these therapies?
- What are the long and short-term prospects of delivering combinations in the clinic?
- How is the pricing and reimbursement situation developing?